Biblio
] Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2021:JCO2100917.
. Natural history of EBV replication and viral load dynamics after alemtuzumab based allogeneic stem cell transplantation. Transplant Cell Ther. 2021.
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study. Blood Adv. 2019;3(24):4264-4270.